Using 17 α-hydroxyprogesterone caproate to impact rates of recurrent preterm delivery in clinical practice
Authors:
- Andrei RebarberARAndrei Rebarber
- Nathan S. FoxNFNathan S. Fox
- Chad K. KlauserCKChad K. Klauser
- Niki B. IstwanNINiki B. Istwan
- Debbie J. RheaDRDebbie J. Rhea
- Gary J. StanzianoGSGary J. Stanziano
- Daniel H. SaltzmanDSDaniel H. Saltzman
- 22 February 2010
- journal article
- research article
- Published by Taylor & Francis in The Journal of Maternal-Fetal & Neonatal Medicine
- Vol. 23 (10) , 1139-1142
Abstract
Objective. Evaluation of an outpatient 17 α-hydroxyprogesterone caproate (17P) administration programme. Methods. A retrospective analysis of data collected from patients with a history of preterm birth (PTB) and current singleton gestation enrolled between 16.0 and 20.9 weeks' gestational age (GA) for weekly outpatient 17P administration and nursing assessment between 7/2004 and 12/2007 was conducted (n = 3139). Results. The population was mostly white (50.3%), 18–35 years old (77.7%), and married (67.0%). Median GA at 17P initiation and stop was 17.4 (16.0, 20.9) weeks and 35.1 (18.6, 37.4) weeks. Mean injections per patient were 16.5 ± 4.9, at an interval of 7.2 days. Median GA at delivery was 37.3 (18.6, 44.0) weeks. Rate of recurrent spontaneous PTB was 29.8%, with 15.5% and 7.0% with PTB at Conclusions. This represents the largest cohort reported to date of patients prescribed 17P therapy in clinical practice to prevent recurrent spontaneous PTB.Keywords
This publication has 11 references indexed in Scilit:
- ACOG Committee Opinion No. 419: Use of Progesterone to Reduce Preterm BirthObstetrics & Gynecology, 2008
- Impact of the recent randomized trials on the use of progesterone to prevent preterm birth: A 2005 follow-up surveyAmerican Journal of Obstetrics and Gynecology, 2006
- 17 Hydroxyprogesterone for the Prevention of Preterm DeliveryObstetrics & Gynecology, 2005
- ACOG Committee on Obstetric Practice Number 291, November 2003: Use of Progesterone to Reduce Preterm BirthObstetrics & Gynecology, 2003
- Prevention of Recurrent Preterm Delivery by 17 Alpha-Hydroxyprogesterone CaproateNew England Journal of Medicine, 2003
- Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: A randomized placebo-controlled double-blind studyAmerican Journal of Obstetrics and Gynecology, 2003
- Genital and nongenital teratogenesis of prenatal progestogen therapy: The effects of 17α-hydroxyprogesterone caproate on embryonic and fetal development and endochondral ossification in the C57B1/6J mouseAmerican Journal of Obstetrics and Gynecology, 1993
- A meta‐analysis of randomized control trials of progestational agents in pregnancyBJOG: An International Journal of Obstetrics & Gynaecology, 1989
- Evaluation of the teratogenic potential of Delalutin (17α‐hydroxyprogesterone caproate) in miceTeratology, 1983
- Teratology in the Macaca mulattaTeratology, 1968